NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
Clinical Trials
38 trialsNCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT03713294 2025-06-24
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03269136 2025-03-18
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Pfizer
Phase 1 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT02939183 2024-09-26
INTREPID-1
Amgen
Phase 1 Completed
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT03202628 2023-09-21
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01734928 2023-06-06
OPTIMISMM
Celgene
Phase 3 Completed
NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
NCT03439280 2023-02-24
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Takeda
Phase 1/2 Completed
NCT01495598 2022-11-01
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02654132 2022-11-01
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Bristol-Myers Squibb
Phase 2 Completed
NCT01712789 2022-01-10
STRATUS
Celgene
Phase 3 Completed
NCT01421186 2021-11-16
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
MorphoSys AG
Phase 1/2 Completed
NCT02612779 2021-07-02
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Bristol-Myers Squibb
Phase 2 Completed
NCT01177735 2021-04-22
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT01570387 2020-09-22
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT01212952 2020-04-17
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00669578 2019-12-30
CC-4047 in Treating Patients With Myelofibrosis
Mayo Clinic
Phase 1/2 Completed
NCT00463385 2019-11-20
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Celgene
Phase 2 Completed
NCT01324947 2019-11-19
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Celgene
Phase 3 Completed
NCT01178281 2019-07-17
RESUME
Celgene
Phase 3 Completed
NCT01159574 2019-06-11
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Weill Medical College of Cornell University
Phase 2 Completed
NCT00946270 2019-06-10
Pomalidomide for Myelofibrosis Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT01311687 2018-10-24
NIMBUS
Celgene
Phase 3 Completed
NCT01794039 2018-08-21
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
Mayo Clinic
Phase 2 Completed
NCT00558896 2018-04-18
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT01432600 2017-05-23
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02011113 2016-11-01
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 2 Completed
NCT01319422 2016-08-11
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Yale University
Phase 2 Completed
NCT00833833 2016-04-27
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 1/2 Completed
NCT00540579 2013-03-13
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
SCRI Development Innovations, LLC
Phase 1/2 Completed